Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C.
Tursi
Antonio
A
D000998:Antiviral Agents / Q000009:adverse effects*; D002908:Chronic Disease; D003093:Colitis, Ulcerative / Q000150:complications / Q000209:etiology*; D004487:Edema / Q000473:pathology; D005838:Genotype; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007107:Immune System; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D007372:Interferons / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D007372:Interferons; C100416:peginterferon alfa-2a